Foghorn Therapeutics appoints Alfonso Quintás-Cardama as CMO; Sam Agresta departs Sept 11, 2023

Foghorn Therapeutics Inc.

Samuel Agresta steps down as CMO effective September 11, 2023; will consult through early January 2024.
Alfonso Quintás-Cardama appointed CMO effective September 11, 2023; previously CMO at TCR2 Therapeutics.
Dr. Quintás-Cardama helped develop Kymriah (tisagenlecleucel) at Novartis and led cell therapy clinical dev at GSK.
He was a faculty member at MD Anderson Cancer Center (2009-2014) developing targeted agents for myeloid malignancies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.